首页> 美国政府科技报告 >Development of Pain Endpoint Models for Use in Prostate Cancer Clinical Trials and Drug Approval.

【24h】

Development of Pain Endpoint Models for Use in Prostate Cancer Clinical Trials and Drug Approval.

机译：开发用于前列腺癌临床试验和药物批准的疼痛终点模型。

获取原文

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Basch, E.; Bennett, A.;
展开▼
作者单位

展开▼
年度 2017
页码 1-13
总页数 13
原文格式 PDF
正文语种 eng
中图分类
关键词
Prostate cancer; Clinical trials; Drug therapy; Pain; Resistance(biology); Therapeutics; Oncology; Metastatic castrate resistant prostate cancer; Fda; Study endpoints;

机译：前列腺癌;临床试验;药物治疗;疼痛;抵抗（生物学）;治疗学;肿瘤学;转移性去势抵抗性前列腺癌; Fda;研究终点;

相似文献

外文文献
中文文献
专利

1. Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: Formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials [J] . BelleraC.A., PulidoM., GourgouS., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2013,第4期

机译：CANcer试验中评估事件到达时间终点的定义的协议（DATECAN）：正式共识方法，用于制定癌症临床试验中标准化事件到达时间终点的指南
2. Clinical endpoints for drug development in prostate cancer. [J] . Ramiah V, George DJ, Armstrong AJ Current opinion in urology . 2008,第3期

机译：前列腺癌药物开发的临床终点。
3. Development and Qualification of a Drug‐Disease Modeling Platform to Characterize Clinically Relevant Endpoints in Type 2 Diabetes Trials [J] . Gaitonde Puneet, Hurtado Felipe K., Garhyan Parag, Clinical Pharmacology and Therapeutics . 2018,第4期

机译：毒品疾病建模平台的开发和资格，以表征2型糖尿病试验中的临床相关终点
4. Clinical Models for Testing Chemopreventative Agents in Prostate Cancer and Overview of SELECT: The Selenium and Vitamin E Cancer Prevention Trial [C] . Eric A. Klein International Society of Cancer Chemoprevention . 2003

机译：用于测试前列腺癌中化学预防剂的临床模型及选择：硒和维生素E癌预防试验
5. Clinical predictive value of pre-clinical cancer models: A study of the predictive value of the in vitro cell line, human xenograft and murine allograft pre-clinical cancer models for phase II clinical trials of cytotoxic cancer drugs [D] . Voskoglou-Nomikos, Theodora 2001

机译：临床前癌症模型的临床预测价值：体外细胞系，人异种移植和小鼠同种异体移植临床前癌症模型对细胞毒性癌症药物II期临床试验的预测价值研究
6. Editorial Commentary: A Collaborative Model for Endpoint Development: Advancing the Science of Antibacterial Drug Clinical Trials [O] . Joseph G. Toerner, Edward Cox -1

机译：社论评论：终点开发的协作模型：推进抗菌药物临床试验的科学
7. Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin [O] . Jason Gee, Howard Bailey, KyungMann Kim, 2013

机译：II期开放标签，临床局部前列腺癌和高级销患者中中间端点生物标志物调节的多中心临床试验。
8. Development of Pain Endpoint Models for Use in Prostate Cancer Clinical Trials and Drug Approval. [R] . Basch, E., Bennett, A. 2013

机译：开发用于前列腺癌临床试验和药物批准的疼痛终点模型。

Development of Pain Endpoint Models for Use in Prostate Cancer Clinical Trials and Drug Approval.

著录项

引文网络

相似文献

相关主题

期刊订阅